Asymmetric synthesis of L‐[4‐13C]glutamic acid and glutamine

L ‐[4‐^l3C]Glutamic acid ( 1 ) and L ‐[4‐¹³C]glutamine ( 2 ) were synthesized from sodium [2‐¹³C]acetate ( 5 ) and Dellaria's oxazinone 3 as a chiral glycine equivalent. Sodium [2‐¹³C]acetate ( 5 ) was converted to [2‐¹³C]acrylate 4 . Diastereoselective Michael addition of the enolate of 3 to the acrylate 4 proceeded with high diastereoselectivity to give the adduct 12 . Reductive cleavage of the C–S bond, ethanolysis, hydrogenolysis and hydrolysis gave L ‐[4‐¹³C]glutamic acid ( 1 ). L ‐[4‐¹³C]Glutamine ( 2 ) was synthesized from 1 in 4 steps. Copyright © 2006 John Wiley & Sons, Ltd.     

Asymmetric synthesis of L‐[4‐13C]lysine by alkylation of oxazinone derivative as a chiral glycine equivalent

L ‐[4‐¹³C]Lysine ( 2 ) was synthesized from sodium [2‐¹³C]acetate ( 3 ) and Dellaria's oxazinone 1 as a chiral glycine equivalent. Wittig reaction of the glycinal 7 and ¹³C‐labeled phosphonium ylide 5 , prepared from sodium [2‐¹³C]acetate ( 3 ), gave the α, β ‐ unsaturated ester 8 . The ester 8 was converted to the allylic bromide 10 . Alkylation of the oxazinone 1 with 10 proceeded with high diastereoselectivity. Ethanolysis, hydrogenation of the double bond with diimide, removal of the chiral auxiliary, and hydrolysis gave L ‐[4‐¹³C]lysine ( 2 ). Copyright © 2004 John Wiley & Sons, Ltd.     

Synthesis of a stable‐isotope‐labeled biotinylated pentasaccharide conjugate (EP217609), a dual‐effect anticoagulant drug

EP217609 is a neutralizable dual‐effect anticoagulant under clinical investigation in cardiopulmonary bypass during cardiac surgery. Stable‐isotope‐labeled EP217609 was synthesized as an internal standard for mass spectrometry in support of bioassays. EP217609 was obtained in six steps starting from three building blocks in an overall yield of 42%, with a chemical purity of >99%. Thus, coupling between the N‐protected labeled biotin‐lysine 4 , prepared in three steps from [¹³C,¹⁵N]‐l ‐lysine 2 , and the pentasaccharide‐spacer‐amine 6 was first performed. Removal of the Cbz protective group to 8 followed by coupling of the activated peptidomimetic building‐block 10 gave the immediate precursor of EP217609, which could be obtained after catalytic hydrogenolysis of 1,2,4‐oxadiazol‐5(2H)‐one into amidine.     

An asymmetric synthesis of l‐[3‐13C]alanine

l ‐[3‐¹³C]Alanine was synthesized from [¹³C]methyl iodide by using Dellaria's oxazinone, prepared from phenyl[2‐¹³C]bromoacetate and (S)‐2‐phenylglycinol, as a chiral glycine equivalent. Alkylation of the oxazinone with [¹³C]methyl iodide was achieved with high diastereoselectivity. Hydrolysis and removal of the chiral auxiliary of the alkylated oxazinone gave l ‐[3‐¹³C]alanine. Copyright © 2003 John Wiley & Sons, Ltd.     

Efficient syntheses of benzyl and n‐octyl [1,3‐13C2]acetoacetates,and their application to syntheses of 13C‐labelled pyrrole and 13C‐labelled hymecromone

Benzyl [1‐¹³C]acetate (2a) was prepared via esterification of sodium [1‐¹³C]acetate (1) with benzyl bromide in the presence of 18‐crown‐6‐ether in 97% yield. n‐Octyl [1‐¹³C]acetate (2b) was rapidly obtained by microwave irradiation of 1‐bromooctane and potassium [1‐¹³C]acetate (obtained by salt exchange of 1) absorbed on Al₂O₃ in 82% yield. Solvent‐free Claisen condensation of benzyl or n‐octyl [1‐¹³C]acetate (2a or 2b) in the presence of potassium tert‐butoxide efficiently gave benzyl or n‐octyl [1,3‐¹³C₂]acetoacetate (3a or 3b) in 51 or 68% yield, respectively. Dibenzyl 2,4‐dimethyl[2,4‐¹³C₂]pyrrole‐3,5‐di[¹³C]carboxylate (4) was synthesized from benzyl [1,3‐¹³C₂]acetoacetate (3a) in 54% yield. [2,4‐¹³C₂]Hymecromone (6) (7‐hydroxy‐4‐methyl[2,4‐¹³C₂]coumarin) was obtained from n‐octyl [1,3‐¹³C₂]acetoacetate (3b) and 1,3‐benzenediol (5) in 73% yield. Copyright © 2008 John Wiley & Sons, Ltd.     

Synthesis of highly potent lymphocyte function‐associated antigen‐1 antagonists labeled with carbon‐14 and with stable isotopes,part 3

The drug candidates ( 2 ) and ( 3 ) are highly potent LFA‐1 inhibitors. They were efficiently prepared labeled with carbon‐14 using a palladium‐catalyzed carboxylation of an iodo‐precursor ( 5 ) and sodium formate‐¹⁴C to afford acid [¹⁴C]‐( 6 ), which was coupled via an amide bond to chiral amines ( 7 ) and ( 8 ) in 52% and 48% overall yield, respectively, and with specific activities higher than 56 mCi/mmol and radiochemical purities of 99%. For stable isotopes synthesis, the amine [²H₈]‐( 7 ) was synthesized in three steps from 2‐cyanopyridine‐²H₄ using Kulinkovich‐Szymonik aminocyclopropanation, followed by coupling to L ‐alanine‐2,3,3,3‐²H₄‐N‐t‐BOC, and then removal of the BOC‐protecting group. Amide bond formation with acid ( 6 ) gave [²H₈]‐( 2 ) in 36% overall yield. The amine [¹³C₄,¹⁵N]‐( 8 ) was obtained in two steps using L‐threonine‐¹⁴C₄,¹⁵N and then coupled to acid [¹³C]‐( 6 ) to give [¹³C₅,¹⁵N]‐( 3 ) in 56% overall yield.     

Chemical synthesis of allyl‐[13C6]‐glucuronate

The synthesis of allyl‐[¹³C₆]‐glucuronate from α‐D‐[¹³C₆]‐glucose in five steps is described. Selective protection of the primary alcohol in the glucose with the bulky trityl group followed by acetylation in the same pot gave the fully protected sugar. Removal of the trityl group followed by oxidation of the primary alcohol to the acid and removal of the acetate groups using catalytic amounts of sodium methoxide gave the glucuronic acid. Reaction with allyl bromide using resin‐bound fluoride gave the title compound. Copyright © 2011 John Wiley & Sons, Ltd.     

Synthesis of carbon‐14 labelled (5Z)‐4‐bromo‐5‐(bromomethylene)‐2(5H)‐furanone: a potent quorum sensing inhibitor

The potent quorum sensing inhibitor (5Z)‐4‐bromo‐5‐(bromomethylene)‐2(5H)‐[2‐¹⁴C]furanone has been prepared in five steps in 7.7% overall yield starting from bromo[1‐¹⁴C]acetic acid. Condensation of ethyl bromo[1‐¹⁴C]acetate with ethyl acetoacetate followed by decarboxylation was accelerated by microwave heating to afford [1‐¹⁴C]levulinic acid. Subsequently, bromination and oxidation gave the targeted furan‐2‐one with a radiochemical purity of > 97% and a specific activity of 57 mCi/mmol. Copyright © 2004 John Wiley & Sons, Ltd.     

Synthesis of isotope‐labeled HSP90 inhibitor: [13CD3] and [14C]‐TAK‐459

[¹³CD₃]‐TAK‐459 (1A), an HSP90 inhibitor, was synthesized from [¹³CD₃]‐sodium methoxide in three steps in an overall yield of 29%. The key intermediate [¹³CD₃]‐2‐methoxy‐6‐(4,4,5,5‐tetramethyl‐1,3,2‐dioxaborolan‐2‐yl)pyridine was synthesized in two steps from 2,6‐dibromopyridine and stable isotope‐labeled sodium methoxide. [¹⁴C]‐TAK‐459 (1B) was synthesized from [¹⁴C(U)]‐guanidine hydrochloride in five steps in an overall radiochemical yield of 5.4%. The key intermediate, [¹⁴C]‐(R)‐2‐amino‐7‐(2‐bromo‐4‐fluorophenyl)‐4‐methyl‐7,8‐dihydropyrido[4,3‐d]pyrimidin‐5(6H)‐one, was prepared by microwave‐assisted condensation.     

Synthesis of [1‐13C]‐para‐xylene and [2‐13C]‐para‐xylene

An efficient synthesis of [1‐¹³C]‐para‐xylene ( 1a ) and [2‐¹³C]‐para‐xylene ( 1b ) is described. The incorporation of the label has been achieved by cyclocondensation of suitable 1,5‐bis(bromomagnesio)alkanes with either ethyl [1‐¹³C]acetate or ethyl [¹³C]formate which gave [ring‐¹³C]‐labelled dimethylcyclohexanols. Dehydration of these alcohols followed by dehydrogenation of the intermediate dimethylcyclohexenes furnished the title compounds in 32 and 40% overall yield, respectively. Copyright © 2001 John Wiley & Sons, Ltd.     

The synthesis of isotopically labeled (+)‐2‐aminobicyclo[3.1.0]hexane‐2,6‐carboxylic acid and its 2‐oxa‐ and 2‐thia‐analogs

As part of a program aimed at the design of conformationally constrained analogs of glutamic acid, (+)‐2‐aminobicyclo[3.1.0]hexane‐2,6‐carboxylic acid ( 1 ), identified as a highly potent, selective, group II metabotropic glutamate receptor agonist has been synthesized and studied clinically. Heterocyclic analogs of 1 were subsequently synthesized in which the C‐2 methylene has been replaced by an oxygen atom ( 2 ) or a sulfur atom ( 3 ). C‐14 labeled isotopomers of 1 , 2 and 3 have been synthesized to facilitate pre‐clinical ADME studies. A tritium labeled isotopomer of 1 was also synthesized for use in in vitro experiments. A stable labeled isotopomer of rac‐1 was prepared for use as an internal standard for bioanalytical assays. The key step in each of these syntheses was the reaction of chiral ketone 4 , 5 or 6 with K¹⁴CN/(NH₄)₂CO₃ using the Bucherer–Berg protocol. In the preparation of the stable labeled isotopomer, rac‐4 ‐[¹³ C ₂] was prepared in two steps from ethyl bromoacetate‐[UL‐¹³C₂]; subsequent reaction of rac‐4 ‐[¹³ C ₂] with K¹³CN/¹⁵NH₄Cl/Na₂CO₃, followed by hydrolysis of the hydantoin yielded rac‐1 ‐[¹³ C ₃,¹⁵ N ]. Copyright © 2005 John Wiley & Sons, Ltd.     

Synthesis of selectively labeled histidine and its methylderivatives with deuterium,tritium, and carbon‐14

Isotopologues of l ‐histidine and its N‐methylderivatives labeled with deuterium and tritium at the 5‐position in the imidazole ring were obtained using the isotope exchange method. The deuterium‐labeled isotopologues [5‐²H]‐l ‐histidine, [5‐²H]‐N^τ‐methyl‐l ‐histidine, [5‐²H]‐N^π‐methyl‐l ‐histidine, and [2,5‐²H₂]‐l ‐histidine were synthesized by isotope exchange method carried out in a fully deuterated medium with. The same reaction conditions were applied to synthesize [5‐³H]‐N^τ‐methyl‐l ‐histidine, [5‐³H]‐N^π‐methyl‐l ‐histidine, and [5‐³H]‐l ‐histidine with specific activity of 2.0, 5.0, and 2.6 MBq/mmol, respectively. The N^π‐[methyl‐¹⁴C]‐histamine was obtained with specific activity of 0.23 MBq/mmol in a one‐step reaction by the direct methylation of histamine by [¹⁴C]iodomethane.     

A short synthesis of d‐[1‐14C]‐serine of high enantiomeric purity

Herein, we report a short, three‐step synthesis of d ‐[1‐¹⁴C]‐serine (4) in high enantiomeric purity. Starting from [¹⁴C]‐KCN and 2‐(benzyloxy)acetaldehyde, Strecker reaction using (R)‐1‐phenylethylamine as the chiral auxiliary gave two diastereomeric aminonitriles 1 and 2 in the ratio of 4:3, which were conveniently separated and purified chromatographically. Following hydrolysis and subsequent hydrogenolysis, the purified major diastereomer 1, was smoothly converted to d ‐[1‐¹⁴C]‐serine (4) in an enantiomeric excess of >99%, thus circumventing time intensive chiral HPLC enantiomeric resolution.     

Partial [αMe]Aun scan of [l‐Leu11‐OMe]‐trichogin GA IV,a membrane active synthetic precursor of the natural lipopeptaibol

Abstract: We synthesized using solution‐phase methods three analogs of [l ‐Leu¹¹‐OMe] trichogin GA IV, a membrane active synthetic precursor of the lipopeptaibol antibiotic in which the N‐terminal n‐octanoyl group and each of the three Aib residues in positions 1, 4 and 8 are replaced by an acetyl group and the lipophilic C^α,α‐disubstituted glycine l ‐(αMe)Aun, respectively [partial (αMe)Aun scan]. FT‐IR absorption and CD analyses unequivocally show that the main three‐dimensional structural features of [l ‐Leu¹¹‐OMe] trichogin GA IV are preserved in the analogs. Also, [l ‐Leu¹¹‐OMe] trichogin GA IV and the three N^α‐acetylated l ‐(αMe)Aun analogs exhibit strictly comparable membrane‐modifying properties. Taken together, these results strongly favor the conclusion that a shift of the long hydrocarbon moiety from the N^α‐blocking group to the side‐chain of the 1, 4 or 8 residue does not have any significant effect on the conformational properties or the membrane activity of [l ‐Leu¹¹‐OMe] trichogin GA IV and, by extension, of the natural lipopeptaibol.     

Fluorine‐18 labelling of PNAs functionalized at their pseudo‐peptidic backbone for imaging studies with PET

Peptide nucleic acids (PNAs) form a unique class of synthetic macromolecules, originally designed as ligands for the recognition of double‐stranded DNA, where the deoxyribose phosphate backbone of original DNA is replaced by a pseudo‐peptide N‐(2‐aminoethyl)glycyl backbone, while retaining the nucleobases of DNA. We have previously developed an original method to label oligonucleotide‐based macromolecules with the short‐lived positron‐emitter fluorine‐18 (t_1/2: 109.8 min) using the N‐(4‐[¹⁸F]fluorobenzyl)‐2‐bromoacetamide reagent. Using this method, we herein report the fluorine‐18‐labelling of 13 decameric PNAs ( OLP_1‐13 ), of the same sequence (CTCATACTCT), but presenting selected modification of the pseudo‐peptidic backbone at two or three of the thymine residues (positions 2, 5 and 8). Structural characteristics of these backbone modifications include either an amino acid side chain (L ‐Lys, L ‐Glu, L ‐Leu and L ‐Arg) or a glycosyl moiety (mannose, galactose, fucose, N‐Ac‐galactosamine and N‐Ac‐glucosamine) attached via an appropriate spacer. N‐(4‐[¹⁸F]fluorobenzyl)‐2‐bromoacetamide was synthesized in three radiochemical steps from 4‐cyano‐N,N,N‐trimethylanilinium trifluoromethanesulfonate and HPLC‐purified in 85–90 min (typical production: 3.7–4.8 GBq starting from a batch of 29.6–31.4 GBq of [¹⁸F]fluoride). Conjugation of the fluorine‐18‐labelled bromoacetamide reagent with the PNAs was performed in a mixture of acetonitrile and HEPES buffer (0.1 M, pH 7.9) for 10 min at 60°C and gave the corresponding pure labelled conjugated PNAs ([¹⁸F] c‐OLP_1‐13 ) after RP‐HPLC purification. The whole synthetic procedure, including the preparation of the fluorine‐18‐labelled reagent, provides up to 0.9 GBq (25 mCi) of HPLC‐purified [¹⁸F] c‐OLP_1‐13 in 160 min with a specific radioactivity of 45–65 GBq/µmol (1.2–1.7 Ci/µmol) at the end of synthesis starting from 29.6 to 31.4 GBq (800–850 mCi) of [¹⁸F]fluoride. Copyright © 2004 John Wiley & Sons, Ltd.     

Synthesis of 5‐[4,5‐13C2]‐ and 5‐[1,5‐13C2]aminolevulinic acid

5‐[4,5‐¹³C₂]‐ and 5‐[1,5‐¹³C₂]Aminolevulinic acid (ALA) have been synthesized by the Gabriel condensation of potassium phthalimide with ethyl bromo[1,2‐¹³C₂]acetate (derived from [1,2‐¹³C₂]acetic acid) or ethyl bromo[2‐¹³C]‐acetate (derived from sodium [2‐¹³C]acetate), followed by conversion to the chloride, coupling reaction with 2‐ethoxycarbonylethylzinc iodide derived from ethyl 3‐iodopropionate or 2‐methoxy[¹³C]carbonylethylzinc iodide derived from methyl 3‐iodo[1‐¹³C]propionate (generated from potassium [¹³C]cyanide), and hydrolysis. Copyright © 2002 John Wiley & Sons, Ltd.     

Radiosynthesis and preliminary biodistribution in mice of 6‐deoxy‐6‐[131I]iodo‐L‐ascorbic acid

An ascorbate analog labeled with iodine‐131, 6‐deoxy‐ 6‐[¹³¹I]iodo‐L ‐ascorbic acid was prepared for evaluation as an in vivo tracer of L ‐ascorbic acid. The no‐carrier‐added radiosynthesis was conducted by nucleophilic bromine–iodine exchange between the brominated precursor and sodium [¹³¹I]iodide in 2‐pentanone at 130–140°C. HPLC purification using a reverse‐phase column gave 6‐deoxy‐6‐[¹³¹I]iodo‐L ‐ascorbic acid in radiochemical yield of 36–60% with high radiochemical purity and satisfactory‐specific radioactivity in a total preparation time of 90 min. Biodistribution studies in fibrosarcoma‐bearing mice showed a high uptake in the adrenal glands, accompanied by low activity of tumor accumulation, accumulation properties similar to previous results obtained with ¹⁴C‐labeled ascorbic acid and 6‐deoxy‐6‐[¹⁸F]fluoro‐L ‐ascorbic acid, in spite of high level of deiodination. Copyright © 2009 John Wiley & Sons, Ltd.     

Synthesis of 13C‐labeled derivatives of cysteine for magnetic resonance imaging studies of drug uptake and conversion to glutathione in rat brain

Effects of neurodegeneration have been linked to inefficient detoxification of free radicals due to lowered concentrations of antioxidants, especially glutathione, in the brain. In the biosynthesis of glutathione, cysteine concentration is generally the limiting factor. Glutathione and cysteine administrations are not effective treatments for neurodegeneration because glutathione inefficiently crosses cell membranes and cysteine is neurotoxic at high concentrations. Prodrugs of glutathione and cysteine may have more favorable uptake and/or toxicity profiles. Three such prodrugs were synthesized with a ¹³C‐label such that in vivo uptake of each and conversion to glutathione in the brain could be monitored by magnetic resonance imaging. L‐[3‐¹³C]‐Cysteine was treated with sodium acetate trihydrate and acetic anhydride to give 2(R)‐N‐acetyl‐[3‐¹³C]‐cysteine ([¹³C]‐NAC; 96%). Addition of triphosgene to L‐[3‐¹³C]‐cysteine provided 4(R)‐[5‐¹³C]‐2‐oxothiazolidine‐4‐carboxylic acid ([¹³C]‐OTZ; 65%). A four‐step pathway was used to synthesize ethyl γ‐L‐glutamyl‐[3‐¹³C]‐L‐cysteinate ([¹³C]‐GCEE). L‐[3‐¹³C]‐Cysteine was esterified (100% yield) and then cyclized with acetaldehyde to give ethyl 2(R,S)‐methyl‐[5‐¹³C]‐thiazolidine‐4(R)‐carboxylate (73%) as a mixture of two diastereomers (65:35). The thiazolidine was silylated (bis(trimethylsilyl)trifluoroacetamide) and reacted with N‐phthaloyl‐L‐glutamic anhydride. Treatment with hydrazine afforded ethyl N‐[γ‐4′(S)‐glutamyl]‐2(R,S)‐methyl‐[5‐¹³C]‐thiazolidine‐4(R)‐carboxylate (48%; 73:27 mixture of diastereomers). This was converted to the desired product, [¹³C]‐GCEE (49%), using mercury (II) acetate and hydrogen sulfide.     

Synthesis of C‐14 and C‐13, H‐2‐labeled IKK inhibitor: [14C] and [13C4,D3]‐N‐(6‐chloro‐7‐methoxy‐9H‐pyrido[3,4‐b]indol‐8‐yl)‐2‐methyl‐3‐pyridinecarboxamide

[¹⁴C]‐N‐(6‐Chloro‐7‐methoxy‐9H‐pyrido [3,4‐b]indol‐8‐yl)‐2‐methyl‐3‐pyridinecarboxamide (5B ), an IKK inhibitor, was synthesized from [¹⁴C]‐barium carbonate in two steps in an overall radiochemical yield of 41%. The intermediate, [carboxyl‐¹⁴C]‐2‐methylnicotinic acid, was prepared by the lithiation and carbonation of 3‐bromo‐2‐methylpyridine. [¹³C₄,D₃]‐N‐(6‐chloro‐7‐methoxy‐9H‐pyrido [3,4‐b]indol‐8‐yl)‐2‐methyl‐3‐pyridinecarboxamide (5C ) was synthesized from [1,2,3,4‐¹³C₄]‐ethyl acetoacetate and [D₄]‐methanol in six steps in an overall yield of 2%. [¹³C₄]‐2‐methylnicotic acid, was prepared by condensation of [¹³C₄]‐ethyl 3‐aminocrotonate and acrolein, followed by hydrolysis with lithium hydroxide. Copyright © 2006 John Wiley & Sons, Ltd.     

Synthesis of two potent glucocorticoid receptor agonists labeled with carbon‐14 and stable isotopes

Two potent glucocorticoid receptor agonists were prepared labeled with carbon‐14 and with stable isotopes to perform drug metabolism, pharmacokinetics, and bioanalytical studies. Carbon‐14 labeled (1) was obtained from an enantiopure alkyne (5) via a Sonogashira coupling to a previously reported 5‐amino‐4‐iodo‐[2‐¹⁴C]pyrimidine [¹⁴C]‐(6), followed by a base‐mediated cyclization (1) in 72% overall radiochemical yield. Carbon‐14 labeled (2) was prepared in five steps employing a key benzoic acid intermediate [¹⁴C]‐(13), which was synthesized in one pot from enolization of trifluoromethylketone (12), followed by bromine–magnesium exchange and then electrophile trapping reaction with [¹⁴C]‐carbon dioxide. A chiral auxiliary (S)‐1‐(4‐methoxyphenyl)ethylamine was then coupled to this acid to give [¹⁴C]‐(15). Propargylation and separation of diastereoisomers by crystallizations gave the desired diastereomer [¹⁴C]‐(17) in 34% yield. Sonogashira coupling to iodopyridine (10) followed by cyclization to the azaindole [¹⁴C]‐(18) and finally removal of the chiral auxiliary gave [¹⁴C]‐(2) in 7% overall yield. For stable isotope syntheses, [¹³C₆]‐(1) was obtained in three steps using [¹³C₄]‐(6) and trimethylsilylacetylene‐[¹³C₂] in 26% yield, while [²H₅]‐(2) was obtained by first preparing the iodopyridine [²H₅]‐(10) in five steps. Then, Sonogashira coupling to chiral alkyne (24) and cyclization gave [²H₅]‐(2) in 42% overall yield.